Search

Your search keyword '"OLSZANECKA-GLINIANOWICZ, M."' showing total 244 results
Start Over Author "OLSZANECKA-GLINIANOWICZ, M."
244 results on '"OLSZANECKA-GLINIANOWICZ, M."'

3. Psychological effects of the COVID-19 pandemic – what do we know about them?

Author

GLINIANOWICZ, M., CIURA, D., BURNATOWSKA, E., and OLSZANECKA-GLINIANOWICZ, M.

Abstract

The coronavirus disease 2019 (COVID-19) pandemic was a shock to the whole world. This pandemic caused not only many deaths of people of all ages and health effects that are still difficult to assess, but also economic, and psychological ones. Numerous studies have shown that chronic stress related to social isolation and fear of contagion increased the rates of development of anxiety, depression syndrome, emotional eating, and posttraumatic stress disorder (PTSD). The increased rate of substance use and antidepressant drugs has also been observed. Depression is included in the symptoms of long-COVID syndrome. The data on the deterioration of mental states of children and adolescents during the COVID-19 pandemic are particularly worrying. Some studies have shown increased suicide rates during and after the COVID-19 pandemic. The deterioration of mental health can also have long-term consequences in terms of physical health, for example, emotional eating (EE) associated with depressed mood and anxiety may increase the incidence of binge eating disorder (BED) and addictive eating. Consequently, the number of patients with overweight and obesity and its complications will increase. Problems related to the deterioration of the mental and physical health of the population will increase the burden on the healthcare system. Another important problem is psychological disturbances related to the COVID-19 pandemic developed in healthcare workers. It is necessary to take systemic actions aimed at improving mental health, although it will not be easy in the era of the general global economic crisis, which may deepen the psychological problems from the time of the pandemic. Therefore, the aim of our manuscript is to analyze the available data on the psychological effects of the COVID-19 pandemic on the general population and healthcare workers. [ABSTRACT FROM AUTHOR]

Published
2023

6. The endocrine system function disturbances during and after SARS-CoV-2 infection.

Author

OGAREK, N., OBOZA, P., OLSZANECKA-GLINIANOWICZ, M., and KOCELAK, P.

Abstract

Several receptors for the angiotensin- converting enzyme 2 (ACE2), essential for the penetration of SARS-CoV-2 into cells, are located in the tissues of the endocrine glands. Therefore, it has been suggested that SARSCoV- 2 infection results in the development of hormonal disturbances. To date, several cases of endocrine disturbances related to the dysfunction of all endocrine glands during and after SARS-CoV-2 infection have been described. In this review, we discuss the endocrine system disturbances in patients with COVID-19 and post-COVID-19 syndrome. Based on the case reports described in the literature, patients with COVID-19 may develop endocrine disturbances that are immediately life-threatening. In addition, patients with post- COVID-19 syndrome may develop chronic endocrine disturbances. In summary, the diagnostics of endocrine system disturbances based on clinical symptoms should be taken into account in both patients with COVID-19 and post-COVID-19 syndrome. [ABSTRACT FROM AUTHOR]

Published
2022

16. COVID-19 and obesity: the confrontation of two pandemics.

Author

OBOZA, P., OGAREK, N., OLSZANECKA-GLINIANOWICZ, M., and KOCELAK, P.

Abstract

In 2009, obesity was identified for the first time as a risk factor for increased disease severity and mortality in patients infected with the H1N1 influenza A virus. During the current COVID-19 pandemic, overweight and obesity have been described as independent risk factors of disease severity and mortality due to COVID-19. Excess visceral fat is associated with systemic chronic microinflammation, changes in adipokine release, and oxidative stress. These disturbances result in an impaired immune response, including dysfunction in lymphocyte action and antibody production. Moreover, obesity is a cause of endothelial dysfunction, pro-coagulation state, and enhanced expression of angiotensin-converting enzyme 2 (ACE-2), which contributes to the infection itself and the severity of the disease. We analyzed both the impact of obesity on the severity of COVID-19 and the potential mechanism that influences this severity. Moreover, we discuss the effect of obesity complications on the severity of disease and mortality of patients with COVID-19. Furthermore, we summarize the effectiveness of COVID-19 vaccination in patients with obesity. Finally, we analyzed the effect of the COVID-19 pandemic on mood disturbances and emotional eating and, as a consequence, the development of obesity or an increase in its severity. In summary, the studies conducted during the COVID-19 pandemic indicate that effective obesity treatment should be initiated at once. In addition, the data confirm the need to organize efficient obesity treatment systems for the sake of not only the individual but also society. [ABSTRACT FROM AUTHOR]

Published
2022

18. Pharmacotherapy of patients with benign prostate enlargement and storage symptoms in everyday clinical practice.

Author

ZDROJOWY, R., OWCZAREK, A. J., OLSZANECKA-GLINIANOWICZ, M., ALMGREN-RACHTAN, A., and CHUDEK, J.

Abstract

OBJECTIVE: Storage symptoms significantly deteriorate the quality of life in men with benign prostate enlargement (BPE). Muscarinic receptor antagonists (MRAs) and ß3-adrenergic receptors agonists alone, or in combination with selective a1-alpha-antagonists, are considered the most effective medicines relieving storage symptoms. The aim of this study was to analyze the pharmacotherapy of storage symptoms in men with BPE, and their compliance with the European Association of Urology (EAU) guidelines. PATIENTS AND METHODS: The survey was conducted in 2018 by 261 urologists among 24,613 men with lower urinary tract symptoms (LUTS) and BPE treated pharmacologically. Data concerning recent severity of non-neurological LUTS, storage symptoms and pharmacotherapy were collected. RESULTS: Storage symptoms were reported by 12,356 patients (50.2%) with BPE, more frequently nocturia (75.8%), than urinary urgency (57.8%) and frequency (44.3%). Patients with storage symptoms were more frequently prescribed with MRAs and mirabegron (43.1% vs. 5.0% and 2.4% vs. 0.3%, respectively; p<0.001). Of note, 54.5% of patients with storage symptoms were treated neither with MRAs, nor ß3-adrenergic receptors agonists. In the subgroup with storage symptoms, the increasing severity of LUTS accounted for more frequent prescription of MRA (2.1% vs. 29.1% vs. 42.8% in patients with mild, moderate, and severe LUTS, respectively). Decision tree analysis revealed that patients with urinary urgency and urinary frequency, as well as younger ones with urinary urgency but without urinary frequency, were more frequently prescribed with MRAs. CONCLUSIONS: Urinary urgency and frequency are associated with increased utilization of MRAs in men with BPE in everyday clinical practice. The attitude of Polish urologists toward management of persistent storage symptoms in BPE patients is in line with the EAU guidelines. [ABSTRACT FROM AUTHOR]

Published
2021

19. The association between 24-hour ambulatory blood pressure measurement and selected biochemical and anthropometric parameters in women with polycystic ovary syndrome.

Author

FRANIK, G., BIZOŃ, A., SZYNKARUK-MATUSIAK, M., OSOWSKA, K., DRYŚ, A., OLSZANECKA-GLINIANOWICZ, M., and MADEJ, P.

Abstract

OBJECTIVE: Polycystic ovary syndrome (PCOS) is a complex endocrine and metabolic disorders, which may contribute to the development of cardiovascular diseases. The aim of our study was to evaluate the association between of 24-hour ambulatory blood pressure measurement (ABPM) and selected biochemical and anthropometric parameters in women with PCOS. PATIENTS AND METHODS: The study involved 153 Polish, Caucasian women with PCOS hospitalized in the Department of Endocrinology Gynecology from January 2018 to March 2020. All women had stable body mass during the 3-month period. ABPM was performed using a portable lightweight device with oscillometric technology accepted by International Protocol of European Society of Hypertension (ABPM, HolCARD CR-07, Poland). RESULTS: The first factor taken into consideration was the variability phenotypic subgroups of PCOS on the values of 24-hour ABPM. We revealed that the daytime and night-time systolic and diastolic blood pressure values were significantly higher in phenotype A subgroup than in other subgroups. Moreover, daytime and nighttime systolic and diastolic blood pressure value as well as day-time heart ratio value were significantly higher in subgroup with than without hyperandrogenemia. The obese women with PCOS were characterized of the highest value of all night-time measurements among women with PCOS and normal weight, overweight or obesity. In addition, insulin resistance in the PCOS subgroup was associated with lower value of systolic, diastolic blood pressure and both at daytime and night-time heart rate value than in insulin sensitive PCOS subgroup. CONCLUSIONS: Hyperandrogenemia and obesity were the crucial influencing factors on 24-hour ABPM in the group of women with PCOS. In addition, hypertension, apart from visceral obesity, hyperinsulinemia and insulin resistance, could be considered as component of metabolic syndrome in women with PCOS. [ABSTRACT FROM AUTHOR]

Published
2021

20. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

Author

Pi-Sunyer, Xavier, Astrup, Arne, Fujioka, Ken, Greenway, Frank, Halpern, Alfredo, Krempf, Michel, Lau, David C. W., le Roux, Carel W., Ortiz, Violante, Jensen, Christine Bjorn, Wilding, John P. H., Hamann, A, Barakat, A, Blüher, M, Linn, T, DALLE MOLLE, Alberto, Segner, A, Stübler, P, Tosch-Sisting, R, Pacini, F, Santini, F, Marchesini, G, Rotella, Cm, Invitti, C, Vettor, R, Buscemi, S, Raya, Pm, Freijoo, Fc, de Barbará RG, Carraro, R, Bobillo, Er, de la Cuesta, C, Farsang, C, Csaszar, A, Zahorska-Markiewicz, B, Pupek-Musialik, D, Franek, E, Ostrowska, L, Olszanecka-Glinianowicz, M, Lalic, N, Micic, D, Ludvik, B, Paulweber, B, Prager, R, Scheen, A, Van Gaal, L, Astrup, Av, Hermansen, K, Madsbad, S, Rissanen, A, Nieminen, S, Savolainen, M, Krempf, M, Romon, M, Laville, M, Marre, M, Mira, R, Finucane, F, Veenendaal, A, van Berkum, F, Johannsson-Vidarsdóttir, S, Van de Walle, V, Meesters, E, Hjelmesæth, J, Klemsdal, To, Kulseng, B, Bach-Kliegel, B, Laederach, K, Villiger, L, Golay, A, Bilz, S, Sathyapalan, T, Bain, S, Kumar, S, Le Roux CW, Lean, Me, Mcgowan, B, Rehman, T, Wilding, J, Wittert, G, Caterson, I, Proietto, J, Prins, J, Geloneze Neto, B, Gross, Jl, Chacra, Ar, Halpern, A, Suplicy Hde, A, Chow, Fc, Thacker, Hp, Chadha, M, Chandalia, H, Unnikrishnan, A, Kalra, S, Deshpande, N, Shunmugavelu, M, Deshmukh, Vc, Maislos, M, Lieberman, Gs, Shimon, I, Stern, N, Nabriski, D, Karnieli, E, Shehadeh, N, Gonzalez-Galvez, G, Arechavaleta-Granell Mdel, R, Violante Ortiz RM, Franco, Gm, Gurieva, I, Suplotova, La, Troshina, E, Ruyatkina, La, Voychik, Ea, Martsevich, S, Startseva, Ma, Seeber, Me, Badat, A, Ellis, G, Altuntas, Y, Guler, S, Ulgen, E, Delibasi, T, Chetty, T, Hart, R, Janzen, J, Labonte, I, Lau, D, Liutkus, J, O'Keefe, D, Padwal, R, Ransom, Tp, Tytus, R, Weisnagel, Sj, Adler, J, Aqua, K, Aronoff, Sl, Bedel, Gw, Blevins, Tc, Blumenau, J, Brockmyre, Ap, Call, Rs, Canadas, R, Chaykin, Lb, Cohen, K, Conrow, Jk, Davis, Mg, Downey, Hj, Drosman, Sr, Duckor, S, Farmer, H, Farrell, J, Fehnel, S, Finneran, Mp, Forbes, R, Forker, A, Fredrick, M, Fujioka, K, Geller, Sa, Gill, S, Glaser, L, Greco, Sn, Greenway, Fl, Harper, W, Herman, L, Hoekstra, J, Ingebretsen, R, Ison, R, Jain, Rk, Kaplan, R, Kaster, Sr, Haase, Ga, Kerzner, B, Kirstein, Jl, Koltun, W, Krieger, Dr, Lewis, Ce, Madder, R, Marple, Rn, Mcdermott, Ej, Mello, Cj, Miller, Ab, Mullen, J, Nardandrea, J, O'Neil, P, Pi-Sunyer, F, Pucillo, Rm, Rhee, C, Redrick, S, Pardini, A, Rothman, J, Rubino, Dm, Sellers, G, Smith, T, Byars, Wd, Soufer, J, Sussman, Am, Patrick, K, Schramm, El, Van Cleeff, M, Berg, Sr, Wyatt, Hr, Simon, Ja., Columbia University [New York], Obesity Research Center, The University of Tennessee [Knoxville], Department of Nutrition, Exercise and Sports [Copenhagen], Faculty of Science [Copenhagen], University of Copenhagen = Københavns Universitet (KU)-University of Copenhagen = Københavns Universitet (KU), Scripps Research Institute, Louisiana State University (LSU), Universidade de São Paulo (USP), Centre hospitalier universitaire de Nantes (CHU Nantes), University of Calgary, University College Dublin (UCD), Instituto Mexicano del Seguro Social [Mexico City, Mexico] (IMSS), Novo Nordisk, Department of Obesity and Endocrinology, University of Liverpool, Pi-Sunyer, Xavier, Astrup, Arne, Fujioka, Ken, Greenway, Frank, Halpern, Alfredo, Krempf, Michel, Lau, David C.W., Le Roux, Carel W., Ortiz, Rafael Violante, Jensen, Christine Bjørn, Wilding, John P.H., the SCALE Obesity and Prediabetes NN8022-1839 Study Group [.., Marchesini, Giulio, ], Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D., le Roux, C., Violante Ortiz, R., Jensen, C., Wilding, J. COLLABORATORS: amann A, Barakat A, Blüher M, Linn T, Mölle A, Segner A, Stübler P, Tosch-Sisting R, Pacini F, Santini F, Marchesini G, Rotella CM, Invitti C, Vettor R, Buscemi S, and Raya PM, Freijoo FC, de Barbará RG, Carraro R, Bobillo ER, de la Cuesta C, Farsang C, Csaszar A, Zahorska-Markiewicz B, Pupek-Musialik D, Franek E, Ostrowska L, Olszanecka-Glinianowicz M, Lalic N, Micic D, Ludvik B, Paulweber B, Prager R, Scheen A, Van Gaal L, Astrup AV, Hermansen K, Madsbad S, Rissanen A, Nieminen S, Savolainen M, Krempf M, Romon M, Laville M, Marre M, Mira R, Finucane F, Veenendaal A, van Berkum F, Johannsson-Vidarsdóttir S, Van de Walle V, Meesters E, Hjelmesæth J, Klemsdal TO, Kulseng B, Bach-Kliegel B, Laederach K, Villiger L, Golay A, Bilz S, Sathyapalan T, Bain S, Kumar S, Le Roux CW, Lean ME, McGowan B, Rehman T, Wilding J, Wittert G, Caterson I, Proietto J, Prins J, Geloneze Neto B, Gross JL, Chacra AR, Halpern A, Suplicy Hde A, Chow FC, Thacker HP, Chadha M, Chandalia H, Unnikrishnan A, Kalra S, Deshpande N, Shunmugavelu M, Deshmukh VC, Maislos M, Lieberman GS, Shimon I, Stern N, Nabriski D, Karnieli E, Shehadeh N, Gonzalez-Galvez G, Arechavaleta-Granell Mdel R, Violante Ortiz RM, Franco GM, Gurieva I, Suplotova LA, Troshina E, Ruyatkina LA, Voychik EA, Martsevich S, Startseva MA, Seeber ME, Badat A, Ellis G, Altuntas Y, Guler S, Ulgen E, Delibasi T, Chetty T, Hart R, Janzen J, Labonte I, Lau D, Liutkus J, O'Keefe D, Padwal R, Ransom TP, Tytus R, Weisnagel SJ, Adler J, Aqua K, Aronoff SL, Bedel GW, Blevins TC, Blumenau J, Brockmyre AP, Call RS, Canadas R, Chaykin LB, Cohen K, Conrow JK, Davis MG, Downey HJ, Drosman SR, Duckor S, Farmer H, Farrell J, Fehnel S, Finneran MP, Forbes R, Forker A, Fredrick M, Fujioka K, Geller SA, Gill S, Glaser L, Greco SN, Greenway FL, Harper W, Herman L, Hoekstra J, Ingebretsen R, Ison R, Jain RK, Kaplan R, Kaster SR, Haase GA, Kerzner B, Kirstein JL, Koltun W, Krieger DR, Lewis CE, Madder R, Marple RN, McDermott EJ, Mello CJ, Miller AB, Mullen J, Nardandrea J, O'Neil P, Pi-Sunyer F, Pucillo RM, Rhee C, Redrick S, Pardini A, Rothman J, Rubino DM, Sellers G, Smith T, Byars WD, Soufer J, Sussman AM, Patrick K, Schramm EL, Van Cleeff M, Berg SR, Wyatt HR, Simon JA.

Subjects
Blood Glucose, Counseling, Male, Type 2 diabetes, law.invention, Body Mass Index, Randomized controlled trial, Weight loss, law, Glucagon-Like Peptide 1, Weight management, Subcutaneous, Medicine (all), Reducing, Nausea, General Medicine, Middle Aged, Combined Modality Therapy, 3. Good health, Female, type 2 diabetes, medicine.symptom, Human, medicine.drug, Adult, Diarrhea, medicine.medical_specialty, Diet, Reducing, Injections, Subcutaneous, Injections, Subcutaneou, Placebo, Injections, Double-Blind Method, Internal medicine, Weight Loss, medicine, Humans, Hypoglycemic Agents, Obesity, Exercise, Hypoglycemic Agent, Liraglutide, business.industry, medicine.disease, Weight Lo, Diet, Endocrinology, business, [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition, Body mass index, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Dyslipidemia
Abstract

BACKGROUND: Obesity is a chronic disease with serious health consequences, but weight loss is difficult to maintain through lifestyle intervention alone. Liraglutide, a glucagon-like peptide-1 analogue, has been shown to have potential benefit for weight management at a once-daily dose of 3.0 mg, injected subcutaneously. METHODS: We conducted a 56-week, double-blind trial involving 3731 patients who did not have type 2 diabetes and who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of at least 30 or a BMI of at least 27 if they had treated or untreated dyslipidemia or hypertension. We randomly assigned patients in a 2:1 ratio to receive once-daily subcutaneous injections of liraglutide at a dose of 3.0 mg (2487 patients) or placebo (1244 patients); both groups received counseling on lifestyle modification. The coprimary end points were the change in body weight and the proportions of patients losing at least 5% and more than 10% of their initial body weight. RESULTS: At baseline, the mean (±SD) age of the patients was 45.1±12.0 years, the mean weight was 106.2±21.4 kg, and the mean BMI was 38.3±6.4; a total of 78.5% of the patients were women and 61.2% had prediabetes. At week 56, patients in the liraglutide group had lost a mean of 8.4±7.3 kg of body weight, and those in the placebo group had lost a mean of 2.8±6.5 kg (a difference of -5.6 kg; 95% confidence interval, -6.0 to -5.1; P

Published
2015

21. Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo

Author

UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, Bentley-Lewis, R., Aguilar, D., Riddle, M.C., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H.C., Johnston, P., Køber, L.V., Lawson, F., Lewis, E.F., Maggioni, A.P., McMurray, J.J.V., Ping, L., Probstfield, J.L., Solomon, S.D., Tardif, J.-C., Wu, Y., Pfeffer, M.A., Barkoudah, E., Brahimi, A., Charytan, D., Finn, P., Flynn, A., Hartley, L.H., Henderson, G., Joseph, J., Odutayo, K., Rajesh, V., Vazir, A., Weinrauch, L., Del Prato, S., Petrie, J., Kaplan, A., Lieberman, P., Zuraw, B.L., O'Reilly, E., Patel, K., Allen, P., Scarpa, A., Schattner, M., Granger, C., Rouleau, J., DeMets, D., Chaturvedi, N., Raccah, D., Aizenberg, D., Alvarez, C., Alvarisqueta, A., Baccaro, C., Bartolacci, I., Bordonava, A., Bustamante Labarta, M., Caccavo, A., Calella, P., Cantero, M., Codutti, R., Commendatore, V., Costamagna, O., Cuello, J., Fernandez, A., Garcia Duran, R., Gomez Vilamajo, O., Gorban De Lapertosa, S., Grinfeld, D., Hermida, S., Lagrutta, M., Leon De La Fuente, R., Licheri, A., Luciardi, H., Mackinnon, I., Maffei, L., Marino, J., Montaña, O., Novaretto, L., Orio, S., Orlandini, A., Oviedo, A., Pérez Manghi, F., Patocchi, C., Ramos, H., Rolandi, F., Saa Zarandon, R., Saavedra, S.S., Schiavi, L., Schygiel, P., Trivi, M., Ulla, M., Urdiales, P., Vallejos, J., Vico, M., Waisman, F., Amerena, J., Paul, V., Sangla, K., Van Gaal, W., Yeap, B., Fasching, P., Pieber, T., Danilova, L., Mitkovskaya, N., Sudzhaeva, S., Mathieu, C., Pouleur, Anne-Catherine, Botelho, R.V., Cerqueira, M.J., Chacra, A., Dos Santos, F., Feitosa, G., Forti, A., Golbert, M., Halpern, A., Hissa, M., Lisboa, H., Moraes, J., Nery, M., Quadros, A., Raduan, R., Reis, G., Ribeiro Filho, F., Rollin, G., Rossi, P., Santos, E., Sgarbi, J., Souza, J., Souza, M.R., Delchev, A., Ivanov, V., Klyuchkova, N., Kyoleyan, M., Levterov, G., Lucheva, M., Raev, D., Shumkova, R., Tokmakova, M., Tzekova, M., Yordanov, V., Bailey, G., Bertrand, O., Bhargava, R., Burton, J., Campeau, J., Dumas, R., Filteau, P., Syan, G., Syan, R., Tsoukas, G., Warnica, J.W., Acuña, S., Araneda, G., Bunster, L., Cobos, L., Corbalán, R., Dussaillant, G., Eggers, G., Florenzano, F., Godoy, G., Huidobro, L.A., Lahsen, R., Lanas, F., Larenas, G., Manriquez, L., Medina, M., Palma, J.C., Perez, L., Potthoff, S., Raffo, C., Reyes, E., Saavedra, V., Sanhueza, P., Sepulveda, P., Solis, C.L., Soto, N., Torres, C., Westerberg, B., Yañez, M., Chen, L., Dong, Y., Du, J., Guo, X., Han, P., Hu, T., Jiang, B., Ke, Y., Li, Z., Lu, J., Ma, C., Peng, Y., Shi, Y., Su, G., Tang, B., Xu, B., Yang, J., Yang, Y., Accini, J.L., Arteaga, J.M., Botero, R., Castillo, G., Coronel, J., Cure, C., Garcia, H., Garcia, L., Gomez, C., Hernandez Triana, E., Hernandez, H., Lopez, M., Lopez, P., Manzur, F., Molina, D., Rodriguez, J., Sanchez Vallejo, G., Yupanqui, H., Bronnum-Schou, J., Kaiser Nielsen, P., Nielsen, H., Rønne, H., Rasmussen, S., Rungby, J., Skagen, K., Thomsen, K.K., Torp-Pedersen, C., Duarte-Vera, Y., Marmol Alvear, R., Peñaherrera-Patiño, C., Assaad, S., Shelbaya, S., Ambos, A., Jakovlev, U., Lubi, M., Märtsin, K., Rosenthal, S., Vides, H., Alanko, J., Korsoff, P., Koski, A.-M., Lahtela, J., Nelimarkka, L., Tuomilehto, J., Cariou, B., Catargi, B., Ducloux, R., Hadjadj, S., Kerlan, V., Malecot, J.-M., Petit, C., Rodier, M., Chumburidze, V., Glonti, S., Lominadze, Z., Todua, F., Contzen, C., Marck, C., Fischer, H., Hagenow, A., Himpel-Bönninghoff, A., Kihm, L., Killat, H., Kleinertz, K., Kosch, C., Kreutzmann, K., Lappo, M., Mertes, B., Piechatzek, R., Prohaska, M., Rinke, A., Schellenberg, D., Toursarkissian, N., Arango, J., Gonzalez, R., Granados, A., Herrera, M., Montenegro, P., Munoz, R., Rodriguez, E., Turcios, E., Villalobos, R., Wyss, F., Hatterjee, S., Chopda, M., Chopra, V., Deshpande, N., Dutta, R., Dwivedi, S., Gandhi, P., Gupta, S.K., Gupta, J.B., Gupta, S., Hiregouder, N., Jha, S., Joshi, A., Khan, N., Kumbla, M., Magdum, M., Murthy, K., Prabhu, M., Sahay, R., Sethuraman, S., Shah, N., Shamanna, P., Singh, K.S., Singh, P., Somasekharan, A., Sreenivasamurthy, L., Supe, P., Adawi, F., Atar, S., Cohen, O., Efrati, S., Karnieli, E., Klainman, E., Minuchin, O., Mosenzon, O., Stern, N., Turgeman, Y., Wainstein, J., Aimaretti, G., Berra, C., Ciardullo, A.V., Consoli, A., Cucinotta, D., Di Marco, S., Giorda, C., Giordano, C., Mannucci, E., Orsi, E., Piatti, P., Pontiroli, A., Ponzani, P., Pozzilli, P., Rivellese, A., Akahori, H., Eki, Y., Fujii, K., Hata, Y., Himeno, H., Hirayama, A., Kishimoto, I., Kobayashi, Y., Miyaoka, H., Niiya, T., Nishi, Y., Nozaki, A., Nunohiro, T., Saito, T., Satoh, Y., Takahashi, A., Takahashi, J., Takase, H., Takase, S., Tsuboko, Y., Tsujimoto, M., Tsujino, M., Tsuzuki, M., Watanabe, S., Yamada, T., Chung, W.J., Rim, S., Jang, H., Kim, U., Chung, C.H., Shin, S.-H., Kim, K., Kim, J., Rha, S., Lee, N.H., Kim, C.-J., Park, K.S., Amolina, I., Ducena, K., Helda, R., Konrade, I., Pirags, V., Sime, I., Sokolova, J., Kakariekiene, V., Kavaliauskiene, R., Petrulioniene, Z., Sakalyte, G., Urboniene, A., Zarankiene, R., Uribe, M., Garcia-Hernandez, P., Garza, J., Vazquez-Garcia, A., Gonzalez, J.G., Escalante, M., Zavala, A., Bayram, E., Hernandez-Muñuzuri, J., Ramos, Lopez, G.A., Lujan, J., Garcia-Soria, M., Velasco-Sanchez, R., Rodriguez, I., Jimenez, S., Galeana, C., Lara, S., Garcia-Castillo, A., Castro, M.G., Aguilar-Orozco, R., Lopez Rosas, E., Vidrio, M., Llamas, G., Stobschinski De Alba, C.A., Carranza-Madrigal, J., Cardosa-Torres, F., Cornel, J.H., Dekkers, P., Frederiks, J., Hermans, W., Lok, D., Meeder, J., Nierop, P., Cooper, J., Lappegård, K.T., Nedrebø, B.G., Castro, E., Gonzalez Castillo, B., Gonzalez, E., Nieto Ortega, R., Andrade, M., Calderon, J., Chavez, C., Correa Flores, R.M., Farfan, J., Lu, L., Luque, E., Manrique, H., Mogrovejo, W., Pariona-Javier, M., Pinto, M., Roldan, Y., Zubiate, C., Dans, A., Gomez, M.H., Panelo, A., Rey, N., Sulit, D.J., Sy, R.A., Timonera, M., Bednarski, J., Bijata-Bronisz, R., Bryniarski, L., Busz-Papiez, B., Czajkowska-Kaczmarek, E., Drzewiecka, A., Dulak, E., Gorska, M., Hamankiewicz, M., Janik, K., Kincel, K., Konieczny, M., Lubinski, A., Olszanecka-Glinianowicz, M., Ponikowski, P., Pulka, G., Rekosz, J., Skudlarski, D., Szymkowiak, K., Wilczewski, P., Bragança, N., Duarte, J., Monteiro, P., Rodrigues, E., Vinhas, M., Adina, P.-M., Avram, R.I., Cif, A., Creteanu, G., Dragomir, D., Ferariu, I.E., Iancu, A.-C., Istratoaie, O., Ivanica, G., Lichiardopol, R., Militaru, C., Minescu, B., Onaca, A., Pintilei, E., Podoleanu, C., Pop, L., Popa, B., Ranetti, A.E., Rosu, D., Tase, A., Tesloianu, D.N., Vinereanu, D., Ageev, F., Akhmedzhanov, N., Barbarash, O., Barbarich, V., Belousov, Y., Berns, S., Bokarev, I., Bolshakova, O., Boyarkin, M., Chumakova, G., Dmitry, P., Fitilev, S., Galyavich, A., Glezer, M., Ivanova, L., Kalashnikov, V., Kalashnikova, M., Karpov, Y., Khaisheva, L., Khalimov, Y., Kobalava, Z., Kosmachova, E., Kostenko, V., Koziolova, N., Kulibaba, E., Lesnov, V., Libov, I., Lyamina, N., Markov, V., Moiseev, V., Molchanova, O., Oleynikov, V., Orlikova, O., Panov, A., Rafalskiy, V., Rodionova, T., Samitin, V., Schokotov, V., Shilkina, N., Shogenov, Z., Shustov, S., Shvarts, Y., Sobolev, K., Stryuk, R., Suplotova, L., Viktorova, I., Vishnevsky, A., Vorokhobina, N., Yakusevich, V., Yakushin, S., Zadionchenko, V., Zalevskaya, A., Zalevsky, G., Zateyshchikova, A., Andjelic Jelic, M., Kocic, R., Komnenovic, S., Lalic, K., Lalic, N., Micic, D., Otasevic, P., Pesic, M., Seferovic, P., Stankovic, G., Arnold, S., Burgess, L., Coetzee, K., Dawood, S., Delport, E., Ebrahim, I., Ellis, G., Ismail, S., Kelbe, D., Naidoo, V., Ntsekhe, M., Sebastian, P.J., Siebert, M., Van Zyl, L., Venter, T., Lonso, E., Antorrena, I., Bodi, V., Botella, M., De La Fuente, J., Delgado, E., Duran Garcia, S., Elorza, J., Enciso, F., Gaztambide, S., Marin, F., Martin, V., Mauricio, D., Soto, A., Vida, M., Boberg, G., Jörneskog, G., Jendle, J., Mathiesen, U., Svensson, K.-A., Torstensson, I., Vasko, P., Moccetti, T., Chiang, C.-E., Chiu, Y.-W., Huang, T.-Y., Lu, C.-H., Pei, D., Shyu, K.-G., Ueng, K.-C., Wang, T.-D., Abid, M., Ben Abdallah, N., Haouala, H., Slimane, H., Zidi, B., Bascil Tutuncu, N., Camsari, A., Delibasi, T., Dinccag, N., Kultursay, H., Oto, A., Sahin, M., Saygili, F., Yigit, Z., Zorkun, C., Karpenko, O., Korpachev, V., Koval, O., Maslyanko, V., Perepelytsya, M., Pertseva, T., Petrosyan, O., Rudenko, L., Sychov, O., Synenko, V., Tseluyko, V., Zhuravleva, L., Al Mahmeed, W., Kaddaha, G.M., Andrews, R., Bain, S., Basu, A., Bhatnagar, D., Bickerton, A., Browne, D., Gibson, M., Hammond, P., Hanna, F., Issa, B., Jaap, A., Joseph, F., Jude, E., Kelly, C., Khan, A., Malik, R., Mukhopadhyay, B., O'Kane, M., Rayman, G., Robinson, A., Rooney, D., Sainsbury, C., Saravanan, P., Shakher, J., Singh, B., Turner, J., Whitelaw, D., Wilding, J., Wiles, P., Adenuga, B., Ahmad, Z., Akinboboye, O., Akright, L., Alappat, P., Alawad, M., Alfonso, T., Alimard, R., Alzohaili, O., Ariani, M., Arora, C., Azad, N., Azzam, S., Benjamin, S., Block, B., Borzadek, E., Breisblatt, W., Bright, T., Byrd, L., Chiou, C., Chochinov, R., Christensen, T., Christofides, E., Cohen, R., Dawood, G., De Souza, J., Dempsey, M., Eagerton, D., East, C., Elder, C., Fernando, R., Fogelfeld, L., Foucauld, J., French, W., Frohnauer, M., Gaffney, M., Gangopadhyay, S., Gogia, H., Gosmanov, A., Greenberg, C., Greenway, F., Hanna, E., Hargrove, J., Harris, A., Harris, B., Hart, T., Herrington, D., Hewitt, M., Howard, D., Izuora, K., Jetty, P., Kapoor, A., Kasper, J.F., Kelehan, S., Kelly, R., Kereiakes, D., Khaira, A., Khan, M., Khan, S., Korban, E., Kosiborod, M., Laguerre, J., Larocque, J., Latif, K., Lester, F., Levin, P., Levine, S., Li, C., Lovell, C., Lupovitch, S., Madu, I.-J., Mahabadi, V., Mahmood, A., Maragos, S., Mariash, C., Martin, P., Mathew, J., May, M., Mayfield, R., McCall, A., Mcdaniel, C., Mcgrew, F., Mckenzie, M., Mefford, I., Mehta, A., Mikdadi, G., Mikhail, M., Monchamp, T., Moore, C., Moran, M., Morrar, N., Mosley, J., Mulford, M., Murray, J., Nakhle, S., Nallasivan, M., Odio, A., Oh, C., Olelewe, S., Palchick, B., Paliwal, Y., Papademetriou, V., Parikh, N., Patel, S., Phillips, L., Pitts, T., Prieto, F., Puttnam, R., Quyyumi, A., Randhawa, P., Rendell, M., Rhie, F., Roberts, J., Robinson, J., Robinson, M., Rubino, J., Ryan, E., Saathoff, S., Sachmechi, I., Saifi, A., Salacata, A., Sanders, R., Sanson, J., Savin, V., Schabauer, A., Schmedtje, J., Schwartz, A., Scott, C., Selagamsetty, M., Shannon, M., Shaw, S., Singal, D., Sjoberg, R., Smith, K., Sofley, C., Sonn, A., Sorof, S., Soroka, E., Spellman, C.W., Steinhoff, J., Suresh, D., Tahir, M., Tanenberg, R., Thawani, H., Thomson, S., Thrasher, J., Trachtenbarg, D., Trotta, M., Tuan, W., Twahirwa, M., Umpierrez, G., Vaid, B., Vance, C., Wang, T., Warner, A., Watson, H., Weber, S., Webster, B., Weindorff, K., Welch, M., Welker, J., White, A., White, L., Williams, M., Wu, W.-C., Wynne, A., Yocono, M., Yuen, K., UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, Bentley-Lewis, R., Aguilar, D., Riddle, M.C., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H.C., Johnston, P., Køber, L.V., Lawson, F., Lewis, E.F., Maggioni, A.P., McMurray, J.J.V., Ping, L., Probstfield, J.L., Solomon, S.D., Tardif, J.-C., Wu, Y., Pfeffer, M.A., Barkoudah, E., Brahimi, A., Charytan, D., Finn, P., Flynn, A., Hartley, L.H., Henderson, G., Joseph, J., Odutayo, K., Rajesh, V., Vazir, A., Weinrauch, L., Del Prato, S., Petrie, J., Kaplan, A., Lieberman, P., Zuraw, B.L., O'Reilly, E., Patel, K., Allen, P., Scarpa, A., Schattner, M., Granger, C., Rouleau, J., DeMets, D., Chaturvedi, N., Raccah, D., Aizenberg, D., Alvarez, C., Alvarisqueta, A., Baccaro, C., Bartolacci, I., Bordonava, A., Bustamante Labarta, M., Caccavo, A., Calella, P., Cantero, M., Codutti, R., Commendatore, V., Costamagna, O., Cuello, J., Fernandez, A., Garcia Duran, R., Gomez Vilamajo, O., Gorban De Lapertosa, S., Grinfeld, D., Hermida, S., Lagrutta, M., Leon De La Fuente, R., Licheri, A., Luciardi, H., Mackinnon, I., Maffei, L., Marino, J., Montaña, O., Novaretto, L., Orio, S., Orlandini, A., Oviedo, A., Pérez Manghi, F., Patocchi, C., Ramos, H., Rolandi, F., Saa Zarandon, R., Saavedra, S.S., Schiavi, L., Schygiel, P., Trivi, M., Ulla, M., Urdiales, P., Vallejos, J., Vico, M., Waisman, F., Amerena, J., Paul, V., Sangla, K., Van Gaal, W., Yeap, B., Fasching, P., Pieber, T., Danilova, L., Mitkovskaya, N., Sudzhaeva, S., Mathieu, C., Pouleur, Anne-Catherine, Botelho, R.V., Cerqueira, M.J., Chacra, A., Dos Santos, F., Feitosa, G., Forti, A., Golbert, M., Halpern, A., Hissa, M., Lisboa, H., Moraes, J., Nery, M., Quadros, A., Raduan, R., Reis, G., Ribeiro Filho, F., Rollin, G., Rossi, P., Santos, E., Sgarbi, J., Souza, J., Souza, M.R., Delchev, A., Ivanov, V., Klyuchkova, N., Kyoleyan, M., Levterov, G., Lucheva, M., Raev, D., Shumkova, R., Tokmakova, M., Tzekova, M., Yordanov, V., Bailey, G., Bertrand, O., Bhargava, R., Burton, J., Campeau, J., Dumas, R., Filteau, P., Syan, G., Syan, R., Tsoukas, G., Warnica, J.W., Acuña, S., Araneda, G., Bunster, L., Cobos, L., Corbalán, R., Dussaillant, G., Eggers, G., Florenzano, F., Godoy, G., Huidobro, L.A., Lahsen, R., Lanas, F., Larenas, G., Manriquez, L., Medina, M., Palma, J.C., Perez, L., Potthoff, S., Raffo, C., Reyes, E., Saavedra, V., Sanhueza, P., Sepulveda, P., Solis, C.L., Soto, N., Torres, C., Westerberg, B., Yañez, M., Chen, L., Dong, Y., Du, J., Guo, X., Han, P., Hu, T., Jiang, B., Ke, Y., Li, Z., Lu, J., Ma, C., Peng, Y., Shi, Y., Su, G., Tang, B., Xu, B., Yang, J., Yang, Y., Accini, J.L., Arteaga, J.M., Botero, R., Castillo, G., Coronel, J., Cure, C., Garcia, H., Garcia, L., Gomez, C., Hernandez Triana, E., Hernandez, H., Lopez, M., Lopez, P., Manzur, F., Molina, D., Rodriguez, J., Sanchez Vallejo, G., Yupanqui, H., Bronnum-Schou, J., Kaiser Nielsen, P., Nielsen, H., Rønne, H., Rasmussen, S., Rungby, J., Skagen, K., Thomsen, K.K., Torp-Pedersen, C., Duarte-Vera, Y., Marmol Alvear, R., Peñaherrera-Patiño, C., Assaad, S., Shelbaya, S., Ambos, A., Jakovlev, U., Lubi, M., Märtsin, K., Rosenthal, S., Vides, H., Alanko, J., Korsoff, P., Koski, A.-M., Lahtela, J., Nelimarkka, L., Tuomilehto, J., Cariou, B., Catargi, B., Ducloux, R., Hadjadj, S., Kerlan, V., Malecot, J.-M., Petit, C., Rodier, M., Chumburidze, V., Glonti, S., Lominadze, Z., Todua, F., Contzen, C., Marck, C., Fischer, H., Hagenow, A., Himpel-Bönninghoff, A., Kihm, L., Killat, H., Kleinertz, K., Kosch, C., Kreutzmann, K., Lappo, M., Mertes, B., Piechatzek, R., Prohaska, M., Rinke, A., Schellenberg, D., Toursarkissian, N., Arango, J., Gonzalez, R., Granados, A., Herrera, M., Montenegro, P., Munoz, R., Rodriguez, E., Turcios, E., Villalobos, R., Wyss, F., Hatterjee, S., Chopda, M., Chopra, V., Deshpande, N., Dutta, R., Dwivedi, S., Gandhi, P., Gupta, S.K., Gupta, J.B., Gupta, S., Hiregouder, N., Jha, S., Joshi, A., Khan, N., Kumbla, M., Magdum, M., Murthy, K., Prabhu, M., Sahay, R., Sethuraman, S., Shah, N., Shamanna, P., Singh, K.S., Singh, P., Somasekharan, A., Sreenivasamurthy, L., Supe, P., Adawi, F., Atar, S., Cohen, O., Efrati, S., Karnieli, E., Klainman, E., Minuchin, O., Mosenzon, O., Stern, N., Turgeman, Y., Wainstein, J., Aimaretti, G., Berra, C., Ciardullo, A.V., Consoli, A., Cucinotta, D., Di Marco, S., Giorda, C., Giordano, C., Mannucci, E., Orsi, E., Piatti, P., Pontiroli, A., Ponzani, P., Pozzilli, P., Rivellese, A., Akahori, H., Eki, Y., Fujii, K., Hata, Y., Himeno, H., Hirayama, A., Kishimoto, I., Kobayashi, Y., Miyaoka, H., Niiya, T., Nishi, Y., Nozaki, A., Nunohiro, T., Saito, T., Satoh, Y., Takahashi, A., Takahashi, J., Takase, H., Takase, S., Tsuboko, Y., Tsujimoto, M., Tsujino, M., Tsuzuki, M., Watanabe, S., Yamada, T., Chung, W.J., Rim, S., Jang, H., Kim, U., Chung, C.H., Shin, S.-H., Kim, K., Kim, J., Rha, S., Lee, N.H., Kim, C.-J., Park, K.S., Amolina, I., Ducena, K., Helda, R., Konrade, I., Pirags, V., Sime, I., Sokolova, J., Kakariekiene, V., Kavaliauskiene, R., Petrulioniene, Z., Sakalyte, G., Urboniene, A., Zarankiene, R., Uribe, M., Garcia-Hernandez, P., Garza, J., Vazquez-Garcia, A., Gonzalez, J.G., Escalante, M., Zavala, A., Bayram, E., Hernandez-Muñuzuri, J., Ramos, Lopez, G.A., Lujan, J., Garcia-Soria, M., Velasco-Sanchez, R., Rodriguez, I., Jimenez, S., Galeana, C., Lara, S., Garcia-Castillo, A., Castro, M.G., Aguilar-Orozco, R., Lopez Rosas, E., Vidrio, M., Llamas, G., Stobschinski De Alba, C.A., Carranza-Madrigal, J., Cardosa-Torres, F., Cornel, J.H., Dekkers, P., Frederiks, J., Hermans, W., Lok, D., Meeder, J., Nierop, P., Cooper, J., Lappegård, K.T., Nedrebø, B.G., Castro, E., Gonzalez Castillo, B., Gonzalez, E., Nieto Ortega, R., Andrade, M., Calderon, J., Chavez, C., Correa Flores, R.M., Farfan, J., Lu, L., Luque, E., Manrique, H., Mogrovejo, W., Pariona-Javier, M., Pinto, M., Roldan, Y., Zubiate, C., Dans, A., Gomez, M.H., Panelo, A., Rey, N., Sulit, D.J., Sy, R.A., Timonera, M., Bednarski, J., Bijata-Bronisz, R., Bryniarski, L., Busz-Papiez, B., Czajkowska-Kaczmarek, E., Drzewiecka, A., Dulak, E., Gorska, M., Hamankiewicz, M., Janik, K., Kincel, K., Konieczny, M., Lubinski, A., Olszanecka-Glinianowicz, M., Ponikowski, P., Pulka, G., Rekosz, J., Skudlarski, D., Szymkowiak, K., Wilczewski, P., Bragança, N., Duarte, J., Monteiro, P., Rodrigues, E., Vinhas, M., Adina, P.-M., Avram, R.I., Cif, A., Creteanu, G., Dragomir, D., Ferariu, I.E., Iancu, A.-C., Istratoaie, O., Ivanica, G., Lichiardopol, R., Militaru, C., Minescu, B., Onaca, A., Pintilei, E., Podoleanu, C., Pop, L., Popa, B., Ranetti, A.E., Rosu, D., Tase, A., Tesloianu, D.N., Vinereanu, D., Ageev, F., Akhmedzhanov, N., Barbarash, O., Barbarich, V., Belousov, Y., Berns, S., Bokarev, I., Bolshakova, O., Boyarkin, M., Chumakova, G., Dmitry, P., Fitilev, S., Galyavich, A., Glezer, M., Ivanova, L., Kalashnikov, V., Kalashnikova, M., Karpov, Y., Khaisheva, L., Khalimov, Y., Kobalava, Z., Kosmachova, E., Kostenko, V., Koziolova, N., Kulibaba, E., Lesnov, V., Libov, I., Lyamina, N., Markov, V., Moiseev, V., Molchanova, O., Oleynikov, V., Orlikova, O., Panov, A., Rafalskiy, V., Rodionova, T., Samitin, V., Schokotov, V., Shilkina, N., Shogenov, Z., Shustov, S., Shvarts, Y., Sobolev, K., Stryuk, R., Suplotova, L., Viktorova, I., Vishnevsky, A., Vorokhobina, N., Yakusevich, V., Yakushin, S., Zadionchenko, V., Zalevskaya, A., Zalevsky, G., Zateyshchikova, A., Andjelic Jelic, M., Kocic, R., Komnenovic, S., Lalic, K., Lalic, N., Micic, D., Otasevic, P., Pesic, M., Seferovic, P., Stankovic, G., Arnold, S., Burgess, L., Coetzee, K., Dawood, S., Delport, E., Ebrahim, I., Ellis, G., Ismail, S., Kelbe, D., Naidoo, V., Ntsekhe, M., Sebastian, P.J., Siebert, M., Van Zyl, L., Venter, T., Lonso, E., Antorrena, I., Bodi, V., Botella, M., De La Fuente, J., Delgado, E., Duran Garcia, S., Elorza, J., Enciso, F., Gaztambide, S., Marin, F., Martin, V., Mauricio, D., Soto, A., Vida, M., Boberg, G., Jörneskog, G., Jendle, J., Mathiesen, U., Svensson, K.-A., Torstensson, I., Vasko, P., Moccetti, T., Chiang, C.-E., Chiu, Y.-W., Huang, T.-Y., Lu, C.-H., Pei, D., Shyu, K.-G., Ueng, K.-C., Wang, T.-D., Abid, M., Ben Abdallah, N., Haouala, H., Slimane, H., Zidi, B., Bascil Tutuncu, N., Camsari, A., Delibasi, T., Dinccag, N., Kultursay, H., Oto, A., Sahin, M., Saygili, F., Yigit, Z., Zorkun, C., Karpenko, O., Korpachev, V., Koval, O., Maslyanko, V., Perepelytsya, M., Pertseva, T., Petrosyan, O., Rudenko, L., Sychov, O., Synenko, V., Tseluyko, V., Zhuravleva, L., Al Mahmeed, W., Kaddaha, G.M., Andrews, R., Bain, S., Basu, A., Bhatnagar, D., Bickerton, A., Browne, D., Gibson, M., Hammond, P., Hanna, F., Issa, B., Jaap, A., Joseph, F., Jude, E., Kelly, C., Khan, A., Malik, R., Mukhopadhyay, B., O'Kane, M., Rayman, G., Robinson, A., Rooney, D., Sainsbury, C., Saravanan, P., Shakher, J., Singh, B., Turner, J., Whitelaw, D., Wilding, J., Wiles, P., Adenuga, B., Ahmad, Z., Akinboboye, O., Akright, L., Alappat, P., Alawad, M., Alfonso, T., Alimard, R., Alzohaili, O., Ariani, M., Arora, C., Azad, N., Azzam, S., Benjamin, S., Block, B., Borzadek, E., Breisblatt, W., Bright, T., Byrd, L., Chiou, C., Chochinov, R., Christensen, T., Christofides, E., Cohen, R., Dawood, G., De Souza, J., Dempsey, M., Eagerton, D., East, C., Elder, C., Fernando, R., Fogelfeld, L., Foucauld, J., French, W., Frohnauer, M., Gaffney, M., Gangopadhyay, S., Gogia, H., Gosmanov, A., Greenberg, C., Greenway, F., Hanna, E., Hargrove, J., Harris, A., Harris, B., Hart, T., Herrington, D., Hewitt, M., Howard, D., Izuora, K., Jetty, P., Kapoor, A., Kasper, J.F., Kelehan, S., Kelly, R., Kereiakes, D., Khaira, A., Khan, M., Khan, S., Korban, E., Kosiborod, M., Laguerre, J., Larocque, J., Latif, K., Lester, F., Levin, P., Levine, S., Li, C., Lovell, C., Lupovitch, S., Madu, I.-J., Mahabadi, V., Mahmood, A., Maragos, S., Mariash, C., Martin, P., Mathew, J., May, M., Mayfield, R., McCall, A., Mcdaniel, C., Mcgrew, F., Mckenzie, M., Mefford, I., Mehta, A., Mikdadi, G., Mikhail, M., Monchamp, T., Moore, C., Moran, M., Morrar, N., Mosley, J., Mulford, M., Murray, J., Nakhle, S., Nallasivan, M., Odio, A., Oh, C., Olelewe, S., Palchick, B., Paliwal, Y., Papademetriou, V., Parikh, N., Patel, S., Phillips, L., Pitts, T., Prieto, F., Puttnam, R., Quyyumi, A., Randhawa, P., Rendell, M., Rhie, F., Roberts, J., Robinson, J., Robinson, M., Rubino, J., Ryan, E., Saathoff, S., Sachmechi, I., Saifi, A., Salacata, A., Sanders, R., Sanson, J., Savin, V., Schabauer, A., Schmedtje, J., Schwartz, A., Scott, C., Selagamsetty, M., Shannon, M., Shaw, S., Singal, D., Sjoberg, R., Smith, K., Sofley, C., Sonn, A., Sorof, S., Soroka, E., Spellman, C.W., Steinhoff, J., Suresh, D., Tahir, M., Tanenberg, R., Thawani, H., Thomson, S., Thrasher, J., Trachtenbarg, D., Trotta, M., Tuan, W., Twahirwa, M., Umpierrez, G., Vaid, B., Vance, C., Wang, T., Warner, A., Watson, H., Weber, S., Webster, B., Weindorff, K., Welch, M., Welker, J., White, A., White, L., Williams, M., Wu, W.-C., Wynne, A., Yocono, M., and Yuen, K.

Abstract

Background: Cardiovascular (CV) disease is the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Furthermore, patients with T2DM and acute coronary syndrome (ACS) have a particularly high risk of CV events. The glucagonlike peptide 1 receptor agonist, lixisenatide, improves glycemia, but its effects on CV events have not been thoroughly evaluated. Methods: ELIXA (www.clinicaltrials.gov no. NCT01147250) is a randomized, double-blind, placebo-controlled, parallelgroup, multicenter study of lixisenatide in patients with T2DM and a recent ACS event. The primary aim is to evaluate the effects of lixisenatide on CV morbidity and mortality in a population at high CV risk. The primary efficacy end point is a composite of time to CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. Data are systematically collected for safety outcomes, including hypoglycemia, pancreatitis, and malignancy. Results: Enrollment began in July 2010 and ended in August 2013; 6,068 patients from 49 countries were randomized. Of these, 69% are men and 75% are white; at baseline, the mean ± SD age was 60.3 ± 9.7 years, body mass index was 30.2 ± 5.7 kg/m2, and duration of T2DM was 9.3±8.2 years. The qualifying ACS wasamyocardial infarctionin83% and unstableangina in 17%. The study will continue until the positive adjudication of the protocol-specified number of primary CV events. Conclusion: ELIXA will be the first trial to report the safety and efficacy of a glucagon-like peptide 1 receptor agonist in people with T2DM and high CV event risk. © 2015 Elsevier Inc. All rights reserved.

Published
2015

28. Resting energy expenditure and gut microbiota in obese and normal weight subjects.

Author

KOCEŁAK, P., ŻAK-GOŁAB, A., ZAHORSKA-MARKIEWICZ, B., APTEKORZ, M., ZIENTARA, M., MARTIROSIAN, G., CHUDEK, J., and OLSZANECKA-GLINIANOWICZ, M.

Abstract

OBJECTIVES: It is suggested that gut microbiota play a role in the pathogenesis of obesity enhancing energy utilization from digested food. The influence of gut microbiota on resting energy expenditure (REE) has not been evaluated yet. AIM: The aim of the study is to assess the composition on gut microbiota and its association with REE in obese and normal weight subjects. SUBJECTS AND METHODS: REE measurement and semi-quantitative analysis of gut microbiota composition in aerobic and anaerobic conditions were performed in 50 obese and 30 normal weight subjects without concomitant diseases. RESULTS: A count of bacterial colony was greater in obese than in normal weight subjects. However, the proportion of Bacteroides spp. and Firmicutes was similar in both study groups. A positive correlation between REE (kcal/d) and total bacterial count (r = 0.26, p < 0.05), as well as between REE and the percentage of Firmicutes (r = -0.24, p < 0.05) was found. The multiple regression analysis did not prove an independent impact of total bacterial as well as Bacteroides spp. and Firmicutes counts on REE. CONCLUSIONS: The composition of gut microbiota is not associated with the level of resting energy expenditure. The proportion of Bacteroides and Firmicutes in gut microbiota is not related to body mass. [ABSTRACT FROM AUTHOR]

Published
2013

30. THE EFFECT OF SHORT - TERM EXERCISE ON NITRIC OXIDE (NO) SERUM CONCENTRATIONS IN OVERWEIGHT AND OBESE WOMEN.

Author

Olszanecka-Glinianowicz, M., Zahorska-Markiewicz, B., Plewa, M., and Janowska, J.

Abstract

The article presents the results of a study which investigated the effects of exercise on obese and overweight women's blood levels of nitric oxide (NO). It was found that resting NO levels were significantly higher in both the overweight and obese groups, compared to a lean control group, but post-exercise levels did not differ significantly between the groups.

Published
2008

33. Resting energy expenditure and gut microbiota in obese and normal weight subjects

Author

Kocełak P, Zak-Gołąb A, Zahorska-Markiewicz B, Aptekorz M, Zientara M, Martirosian G, Jerzy Chudek, and Olszanecka-Glinianowicz M

Subjects
Adult, Intestines, Male, Microbiota, Bacteroides, Humans, Female, Obesity, Middle Aged, Energy Metabolism
Abstract

It is suggested that gut microbiota play a role in the pathogenesis of obesity enhancing energy utilization from digested food. The influence of gut microbiota on resting energy expenditure (REE) has not been evaluated yet.The aim of the study is to assess the composition on gut microbiota and its association with REE in obese and normal weight subjects.REE measurement and semi-quantitative analysis of gut microbiota composition in aerobic and anaerobic conditions were performed in 50 obese and 30 normal weight subjects without concomitant diseases.A count of bacterial colony was greater in obese than in normal weight subjects. However, the proportion of Bacteroides spp. and Firmicutes was similar in both study groups. A positive correlation between REE (kcal/d) and total bacterial count (r = 0.26, p0.05), as well as between REE and the percentage of Firmicutes (r = -0.24, p0.05) was found. The multiple regression analysis did not prove an independent impact of total bacterial as well as Bacteroides spp. and Firmicutes counts on REE.The composition of gut microbiota is not associated with the level of resting energy expenditure. The proportion of Bacteroides and Firmicutes in gut microbiota is not related to body mass.

34. Alexithymia, depression, anxiety and binge eating in obese women

Author

Zak-Goła̧b, A., Tomalski, R., Ba̧k-Sosnowska, M., Michał Holecki, Kocełak, P., Olszanecka-Glinianowicz, M., Chudek, J., and Zahorska-Markiewicz, B.

Subjects
Alexithymia, Depression, Binge eating, Obesity, Anxiety
Abstract

Background and Objectives: Alexithymia is a personality trait that may affect the development and course of obesity and effectiveness of treatment. The aim of the study is to assess the prevalence of alexithymia in obese women beginning a weight reduction program and determine the relationships between alexithymia and anxiety, depression, and binge eating. Methods: Obese women (n = 100; age 45 ± 13 yr) completed the following self-report inventories: Toronto Alexithymia Scale (TAS 26), Hospital Anxiety and Depression Scale (HADS), and Binge Eating Scale (BES). Results: Alexithymia was found in 46 patients and was more frequent among women who had attained only primary and vocational education than in those with a higher education level (39.1% vs. 10.9%; p = 0.002) and in those >45 years old than in younger women (30.4% vs. 69.6%; p = 0.03). The frequency of severe depression symptoms was higher in alexithymic women than in non-alexithymic women (19.6% vs. 5.6%; p = 0.03); however, the anxiety state was equally prevalent in both subgroups. The prevalence of alexithymia (52.6% vs. 44.4%) and its level (73.2 ± 8.9 vs. 71.2 ± 11.3 points) were similar in women with and without binge eating disorder. Multivariate mixed linear regression analysis revealed that higher body mass index was associated with primary and vocational education (odds ratio [OR] = 16.69) and severe depression symptoms (OR = 52.45), but not alexithymia. Conclusions: In addition to severe depression and low education level, obesity may predispose for the development of alexithymia. However, alexithymia does not affect the severity of obesity in women.

37. The influence of weight loss on anaerobic threshold in obese women

Author

Zakgołab, A., Zahorska-Markiewicz, B., LANGFORT JÓZEF, Holecki, M., Kocełak, P., Mizia-Stec, K., Olszanecka-Glinianowicz, M., and Chudek, J.

Subjects
ventilatory threshold, lcsh:Sports, lcsh:GV557-1198.995, lactate threshold, Obesity, lcsh:Sports medicine, lcsh:RC1200-1245, anaerobic threshold, Research Article
Abstract

Obesity is associated with decreased physical activity. The aim of the study was to assess the anaerobic threshold in obese and normal weight women and to analyse the effect of weight-reduction therapy on the determined thresholds.42 obese women without concomitant disease (age 30.5 ± 6.9y; BMI 33.6 ± 3.7 kg·m(-2)) and 19 healthy normal weight women (age 27.6 ± 7.0y; BMI 21.2 ± 1.9 kg·m(-2)) performed cycle ergometer incremental ramp exercise test up to exhaustion. The test was repeated in 19 obese women after 12.3 ± 4.2% weight loss. The lactate threshold (LT) and the ventilatory threshold (VT) were determined. Obese women had higher lactate (expressed as oxygen consumption) and ventilator threshold than normal weight women. The lactate threshold was higher than ventilatory one both in obese and normal weight women (1.11 ± 0.21 vs 0.88 ± 0.18 L·min(-1), p0.001; 0.94 ± 0.15 vs 0.79 ± 0.23 L·min(- 1), p0.01, respectively). After weight reduction therapy neither the lactate nor the ventilatory threshold changed significantly. The results concluded that; 1. The higher lactate threshold noted in obese women may be related to the increased fat acid usage in metabolism. 2. Both in obese and normal weight women lactate threshold appears at higher oxygen consumption than ventilatory threshold. 3. The obtained weight reduction, without weight normalisation was insufficient to cause significant changes of lactate and ventilatory thresholds in obese women. Key pointsResults showed that adolescent young female gymnasts have an altered serum inflammatory markers and endothelial activation, compared to their less physically active peers.Physical activities improved immune system.Differences in these biochemical data kept significant after adjustment for body weight and height.

38. Retinol-binding protein 4 (RBP4) as the causative factor and marker of vascular injury related to insulin resistance

Author

Marcin Majerczyk, Olszanecka-Glinianowicz M, Puzianowska-Kuźnicka M, and Chudek J

Subjects
marker, Glucose Transporter Type 4, lcsh:R, lcsh:Medicine, Vascular System Injuries, Atherosclerosis, RBP-4, miażdżyca, Adipose Tissue, Diabetes Mellitus, Type 2, Adipocytes, Humans, Insulin, Female, Obesity, Insulin Resistance, Polymorphism, Retinol-Binding Proteins, Plasma, Biomarkers, polimorfizm
Abstract

One of adipokines involved in the development of insulin resistance is retinol-binding protein 4(RBP4). The physiological role of RBP4 is transport of retinol from the liver to peripheral tissues. One of the first events related to the excessive visceral fat accumulation is the development of inflammation followed by hormonal adipose tissue dysfunction, including excessive RBP4 production. Reduced density of the membrane-type glucose transporter 4 (GLUT4) is considered as a direct cause for the stimulation of RBP4 release to the circulation by adipocytes. Circulating RBP4 inhibits the signal pathways stimulated by insulin in skeletal muscle cells, resulting in the development of insulin resistance. Drugs stimulating receptor peroxisome proliferator-activated gamma (PPARγ) - thiazolidinediones - inhibit the production of RBP4 by adipose tissue and increase the insulin sensitivity of the tissues. Increased secretion of RBP4 stimulates the expression of adhesion molecules in the endothelial cells, promoting development of atherosclerosis and arterial hypertension. Population studies demonstrated an association between serum RBP4 in the circulation, and the severity of atherosclerosis and risk of the cardiovascular events and type 2 diabetes. It also appears that the rbp4 gene functional polymorphisms may influence the risk of metabolic complications of obesity, including vascular injury. Therefore, the concentration of RBP4 in the circulation may be considered both as the causative factor and marker of chronic vascular injury. This article summarizes the current state of knowledge on the potential role of RBP4 in the pathogenesis of cardiovascular diseases, particularly related to insulin resistance.

41. Prevalence of metabolic syndrome and insulin resistance in overweight and obese women according to the different diagnostic criteria

Author

Kocełak P, Jerzy Chudek, and Olszanecka-Glinianowicz M

Subjects
Adult, Blood Glucose, Metabolic Syndrome, Blood Pressure Determination, Middle Aged, Overweight, Lipids, Risk Assessment, Sensitivity and Specificity, Body Height, Body Mass Index, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Predictive Value of Tests, Risk Factors, Prevalence, Humans, Insulin, Female, Obesity, Poland, Insulin Resistance, Waist Circumference, Algorithms, Biomarkers
Abstract

Metabolic syndrome (MS) is a cluster of risk factors favoring the development of type 2 diabetes and cardiovascular diseases. The prevalence of MS diagnosis is dependent of used diagnostic criteria. The aim of the study is to compare the prevalence of MS in overweight and obese women without concomitant diseases according to the different diagnostic criteria and their sensitivity to identify subjects with insulin resistance.The study involved 126 overweight and obese women without concomitant diseases. In all subjects body mass, height, waist circumference and blood pressure were measured and plasma glucose, insulin and lipids levels were determined. MS was diagnosed using WHO, NCEP ATP III, IDF 2005 and IDF 2009 modified criteria. The insulin resistance was assessed based on the homeostatic model assessment insulin resistance (HOMA-IR≥2.5).The prevalence of MS was 43.8%, 43.8%, 38.1% and 18.1% according to IDF 2005, IDF 2009 modified, NCEP ATP III and WHO criteria, respectively. Insulin resistance was diagnosed in 89 women (70.6%). None of MS definitions allowed for proper discrimination of insulin resistant subjects. The highest sensitivity, but lowest specificity of insulin resistant discrimination had both IDF criteria (44.9% and 72.9%, respectively), while the highest specificity WHO criteria was missing sensitivity (91.8% and 17.9%, respectively).On the basis of both IDF criteria MS is diagnosed in significantly larger subset of overweight and obese women. However, NCEP ATPIII and both IDF criteria identify only less than half insulin resistant overweight and obese women as those with MS.

43. The influence of a 3-month weight reduction therapy with Orlistat on serum vitamin B12 and folic acid concentration in obese women.

Author

Holecki, M., Zahorska-Markiewicz, B., Nieszporek, T., Mizia-Stec, K., Olszanecka-Glinianowicz, M., Zak-Gołąb, A., Kocełak, P., and Więcek, A

Subjects
TREATMENT of diseases in women, OVERWEIGHT women, WEIGHT loss, LIPASE inhibitors, VITAMIN B complex, ANTIOBESITY agents, THERAPEUTICS
Abstract

Objective:Serum folic acid, but not the vitamin B12 concentration, was found to be significantly lower in obese subjects than in the control ones.Design:The aim of this study was to examine the levels of serum vitamin B12 and folic acid in obese women before and after weight reduction therapy with Orlistat in comparison to healthy controls with normal body weight.Subjects:Twenty obese women participated in a 3-month weight reduction therapy. The control group consisted of 20 healthy women.Measurements:Body weight and height were measured and BMI was calculated. Body composition was analyzed with the impedance method using a Bodystat analyzer. In all patients before and after 3-month weight reduction therapy, serum concentrations of folic acid and vitamin B12 were assessed.Results:In obese women, serum concentrations of folic acid and vitamin B12 did not change significantly after 3-month weight reduction therapy with Orlistat.International Journal of Obesity (2006) 30, 1017–1018. doi:10.1038/sj.ijo.0803214; published online 24 January 2006 [ABSTRACT FROM AUTHOR]

Published
2006
Full Text
View/download PDF

45. Fibroblast growth factor 21 inversely correlates with survival in elderly population - the results of the Polsenior2 study.

Author

Handzlik G, Owczarek AJ, Więcek A, Mossakowska M, Zdrojewski T, Chudek A, Olszanecka-Glinianowicz M, and Chudek J

Abstract

Fibroblast growth factor 21 (FGF21) is a liver-secreted hormone involved in the regulation of lipid, glucose, and energy metabolism. Its serum concentration increases with age but also is higher in numerous diseases. FGF21 is being investigated for biomarker properties and as a potential therapeutic target. The present study aimed to assess the prognostic value of FGF21 in an older population-based cohort, the PolSenior2 study participants. In the sub-analysis of 3512 individuals, aged 60 and older, stratified according to FGF21 into tertiles, the survival estimate was worse in participants with middle and high levels compared to the lowest tertile. These results were consistent with univariable Cox regression analysis, in which participants in the middle and the high FGF21 tertiles after adjustment for age had 1.43-fold (HR, 1.31; 95% CI, 1.05 - 1.62) and 2.56-fold (HR, 1.94; 95% CI, 1.59 - 2.37) higher risk for mortality, respectively, compared with those in the lowest tertile. In multivariable Cox regression analysis, the highest levels of FGF21 were associated with increased mortality (HR 1.53; 95% CI, 1.22 - 1.92) independently of co-morbidities and blood parameters. These results indicate that higher serum FGF21 concentration is an independent predictor of all-cause mortality in the general population of older adults.

Published
2024
Full Text
View/download PDF

46. Relationships between Premenstrual Syndrome (PMS) and Diet Composition, Dietary Patterns and Eating Behaviors.

Author

Oboza P, Ogarek N, Wójtowicz M, Rhaiem TB, Olszanecka-Glinianowicz M, and Kocełak P

Subjects
Humans, Female, Adult, Nutritional Status, Dietary Patterns, Premenstrual Syndrome, Diet, Feeding Behavior
Abstract

Premenstrual Syndrome (PMS) is a disorder between gynecology and psychiatry which includes cognitive, affective, and somatic symptoms from mild to severe. The most severe form of PMS is premenstrual dysphoric disorder (PMDD) and it is considered a form of depressive disorder. An association between diet composition and the occurrence of PMS and its severity have been suggested. As such, this manuscript discusses the relationships between diet composition, dietary patterns and eating behaviors, and PMS. PubMed, Embase, Cochrane, and Web of Science databases were searched for related studies up to 18 January 2024. A text search with the following keywords singly or in combination was conducted: "Premenstrual syndrome", "Nutrition", "Diet composition", "Dietary patterns", and "Eating behaviors". Studies published so far showed that low intake of simple carbohydrates, fats, salt, and alcohol, and high of fresh, unprocessed foods rich in B vitamins, vitamin D, zinc, calcium, and omega-3 fatty acids may help prevent the onset of PMS and reduce the severity of its symptoms. However, further studies are needed to formulate definitive recommendations for the use of vitamins, micronutrients and other dietary ingredients supplementation in women with PMS to improve functioning, overall well-being, and physical health. Large, randomized, double-blind clinical trials across diverse populations are necessary to formulate clear recommendations for supplementation in women with PMS.

Published
2024
Full Text
View/download PDF

47. Wnt signaling pathway and sclerostin in the development of atherosclerosis and vascular calcification.

Author

Kocełak P, Puzianowska-Kuźnicka M, Olszanecka-Glinianowicz M, and Chudek J

Subjects
Humans, Animals, Genetic Markers, Vascular Calcification metabolism, Vascular Calcification pathology, Atherosclerosis metabolism, Atherosclerosis pathology, Wnt Signaling Pathway, Adaptor Proteins, Signal Transducing metabolism
Abstract

Atherosclerosis is a complex process involving endothelial dysfunction, vascular inflammation, vascular smooth muscle cell (VSMC) proliferation, angiogenesis, and calcification. One of the pathomechanisms of atherosclerosis is the upregulation of Wnt signaling. This study aimed to summarize the current knowledge regarding the role of Wnt signaling and sclerostin in atherosclerosis, vascular calcification, aneurysms, and mortality based on the PubMed database. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendation and identified 160 papers that were included in this systematic review. The published data highlight that the upregulation of Wnt components facilitates the initiation and progression of atherosclerosis, arterial remodeling, VSMCs proliferation and phenotypic transition to the osteoblastic lineage in the arterial wall. This results in protein secretion, cell migration, calcification, fibrosis and aneurysm formation. The transformation of VSMCs into osteoblast-like cells that is observed in atherosclerosis results in sclerostin expression inhibiting the Wnt pathway. Furthermore, it was shown that sclerostin, expressed in atherosclerotic plaques, inhibits aneurysm formation in a mouse model. However, in humans, while the antisclerostin antibody romosozumab inhibits bone resorption, biochemical parameters of endothelial activation and inflammation are not affected, and the incidence of aneurysms is not increased. It was suggested that detecting sclerostin in the calcified aortic atherosclerotic plaques reflects a defense mechanism against Wnt activation and inhibition of atherosclerosis, although this has only been shown in animal models. Moreover, an increased number of vascular cells converted to osteogenic phenotypes results in increased plasma sclerostin concentrations. Therefore, plasma sclerostin derived from bone limits its importance as a global marker of vascular calcification.

Published
2024
Full Text
View/download PDF

48. The Value of Urinary NGAL, KIM-1, and IL-18 Measurements in the Early Detection of Kidney Injury in Oncologic Patients Treated with Cisplatin-Based Chemotherapy.

Author

Szumilas D, Owczarek AJ, Brzozowska A, Niemir ZI, Olszanecka-Glinianowicz M, and Chudek J

Subjects
Humans, Lipocalin-2, Creatinine, Interleukin-18, Kidney, Cisplatin adverse effects, Acute Kidney Injury chemically induced, Acute Kidney Injury diagnosis
Abstract

Cisplatin is still a widely used anticancer drug characterized by significant nephrotoxicity. Acute kidney injury (AKI), diagnosed based on the Kidney Disease: Improving Global Outcomes (KDIGO) criteria, has limitations, including a delayed increase in creatinine. We determined the usefulness of neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and interleukin-18 (IL-18) in diagnosing AKI according to the KDIGO criteria in patients treated with cisplatin. We recruited 21 subjects starting cisplatin-based chemotherapy (Cisplatin-based group) and 11 treated with carboplatin-based chemotherapy or 5-fluorouracil regimens (non-cisplatin-based group). Blood and urine samples were collected during four subsequent cycles of chemotherapy (68 and 38 cycles, respectively). AKI occurred in four patients in the cisplatin-based group (5.9% of 68 cisplatin-based chemotherapy cycles). Among them, three urinary markers were increased by over 100% in two cases, two in one case and one in another. A doubling of at least one investigated parameter was observed more frequently during cisplatin-based chemotherapy (80.3% vs. 52.8%; OR = 3.65, 95% CI: 1.49-8.90; p < 0.01). The doubling of at least one new urinary AKI marker was more common in patients receiving cisplatin and frequently was not associated with overt AKI. Thus, a subclinical kidney injury detected by these markers occurs more frequently than deterioration in kidney function stated with creatinine changes.

Published
2024
Full Text
View/download PDF

49. Regular and Irregular Use and Reasons for Discontinuation of Solifenacin Therapy in Patients with Overactive Bladder Managed by Urologists.

Author

Małkowski M, Almgren-Rachtan A, Olszanecka-Glinianowicz M, Chudek J, and Chłosta P

Abstract

Solifenacin, a selective muscarinic receptor antagonist, is one of the best-tolerated and most effective medicines that relieve storage symptoms in patients with an overactive bladder (OAB). However, the persistence of solifenacin in daily clinical practice remains far below that reported in clinical trials. This study aimed to analyze the adherence of patients to the therapy and the reasons for solifenacin discontinuation and non-regular use in OAB patients managed by urologists. Data concerning non-compliance and the discontinuation of solifenacin, along with the reasons, were collected during two consecutive visits for 64,049 OAB outpatients. Over the two visits, 81.6% of the patients continued therapy, and 88.6% were taking solifenacin regularly. An age ≥ 75 yrs., the male sex, a rural or small-city dwelling, and a prescription of ≥10 mg predicted therapy continuation. The female sex, a higher education, a short or long duration of an OAB, and a non-idiopathic OAB predicted regular use. The persistence of nycturia and urinary incontinence during therapy predicted both discontinuation and non-regular use. Dissatisfaction with therapy was the most frequent reason for discontinuation. In conclusion, an initial prescription of solifenacin at a low dose reduces the chance of OAB symptom improvement and results in more frequent discontinuation. A high rate of discontinuation related to dissatisfaction suggests unrealistic expectations for OAB patients and insufficient education by urologists.

Published
2024
Full Text
View/download PDF

50. Evaluation of adipokines concentrations in plasma, peritoneal, and endometrioma fluids in women operated on for ovarian endometriosis.

Author

Wójtowicz M, Zdun D, Owczarek AJ, Skrzypulec-Plinta V, and Olszanecka-Glinianowicz M

Subjects
Humans, Female, Adipokines, Leptin metabolism, Resistin, Nicotinamide Phosphoribosyltransferase, Adiponectin, Cross-Sectional Studies, Retinol-Binding Proteins, Plasma, Endometriosis surgery, Ovarian Neoplasms
Abstract

Introduction: Some studies indicate the role of selected adipokines in the development of endometriosis. However, a comprehensive assessment of plasma, peritoneal, and endometrioma fluids adipokines concentrations in women with ovarian endometriosis has not yet been performed. Therefore, this study aimed to analyze plasma, peritoneal, and endometrioma fluids selected adipokines concentrations in women operated on for ovarian endometriosis., Materials and Methods: A cross-sectional cohort study involved 56 women operated on for ovarian endometriosis. Body mass, height, and waist circumference were measured, and BMI was calculated. Plasma, peritoneal, and endometrioma fluids adiponectin, leptin, omentin resistin, RBP4, and visfatin/NAMPT were determined by ELISA., Results: The highest plasma levels of adiponectin, leptin, omentin, and RBP4 than in the endometrioma and peritoneal fluids were found, while levels of resistin and visfatin/NAMPT were significantly higher in endometrioma fluid than in plasma and peritoneal fluid. In addition, levels of visfatin/NAMPT were significantly higher in peritoneal fluid than in plasma. There were also positive correlations between leptin, RBP4, and adiponectin levels in endometrioma and peritoneal fluids (ρ = 0.28; p < 0.05; ρ = 0.31; p < 0.05; ρ= 0.32; p < 0.05, respectively). There were no associations between adipokines levels in plasma, endometrioma, and peritoneal fluids and endometriosis stage., Conclusion: Our results show that visfatin/NAMPT and resistin may be locally secreted in endometrioma related to inflammation regardless of the stage of endometriosis., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Wójtowicz, Zdun, Owczarek, Skrzypulec-Plinta and Olszanecka-Glinianowicz.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results